UNSPSC 51362103: Sodium bromide

This classification denotes a sedative and hypnotic and anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LC1V549NOM. European Medicines Agency schedules Sodium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15275MIG. Sodium bromide generally arises in the molecular formula BRNA. The term SODIUM BROMIDE is a United States Homeopathic Pharmacopoeia Name designation. Most nations schedule sodium bromide under HS 28275100 and SITC 52329.

As of Q4 2014, SODIUM BROMIDE remains the US FDA Preferred Term for this commodity. Sodium bromide bears US NLM identifiers UMLS ID C0074730 and NCI Concept Code C83922. SMILES: [Na+].[Br-].

UNSPSC 51362103 Sodium bromide is a Commodity code that in practice sees little state and local procurement activity directly aligned with its nominal chemical scope. The three recent opportunities tagged under this code address pharmaceutical products and drug-management systems rather than sodium bromide as a chemical input: Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB; the Texas Health and Human Services Commission issued an RFI exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers. The apparent mismatch between the code's chemical-commodity designation and the health-system procurement activity it captures suggests either tagging inconsistency in the source data or a broader interpretation of the code within state and local procurement systems that does not align with the UNSPSC taxonomy definition.

The geographic spread across recent activity includes Florida, Texas, and Minnesota, with MMCAP's cooperative structure extending to Oregon and potentially other participating jurisdictions. Seminole County's naloxone procurement, posted June 30, 2026, targets 1,900 units annually with quarterly deliveries to its Community Health Building, using an IFB with a July 26, 2023 deadline and FEMA potential funding. The MMCAP RFP, posted January 20, 2026 with a March 26, 2026 response deadline, requires manufacturers to supply generic pharmaceuticals through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson with contract effectiveness on July 1, 2026, and evaluates proposals on price competitiveness (75 percent), product availability, and compliance with cGMP and Drug Supply Chain Security Act standards. Without confirmed recent opportunities directly addressing sodium bromide procurement, this code warrants monitoring for reclassification or clarification of its actual use within state and local procurement systems.